{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:57:59Z","timestamp":1790657879058,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13300-026-01908-x","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:01:26Z","timestamp":1786683686000},"page":"1519-1535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE\u2122-CN)"],"prefix":"10.1007","volume":"17","author":[{"given":"Linong","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangming","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel M.","family":"Kloer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"1908_CR1","unstructured":"World Obesity Federation. World Obesity Atlas 2022. 2022. https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2022. Accessed May 26 2025."},{"key":"1908_CR2","unstructured":"World Obesity Federation. World Obesity Atlas 2025. 2025. https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2025. Accessed May 26 2025."},{"issue":"5","key":"1908_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019835","volume":"6","author":"D Wang","year":"2011","unstructured":"Wang D, Li Y, Lee SG, et al. Ethnic differences in body composition and obesity related risk factors: study in Chinese and white males living in China. PLoS ONE. 2011;6(5):e19835.","journal-title":"PLoS ONE"},{"issue":"3","key":"1908_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/oby.20995","volume":"23","author":"W He","year":"2015","unstructured":"He W, Li Q, Yang M, et al. Lower BMI cutoffs to define overweight and obesity in China. Obesity Silver Spring. 2015;23(3):684\u201391.","journal-title":"Obesity Silver Spring"},{"issue":"9403","key":"1908_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"WHO Expert Consultation","year":"2004","unstructured":"WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157\u201363.","journal-title":"Lancet"},{"issue":"6","key":"1908_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","volume":"9","author":"XF Pan","year":"2021","unstructured":"Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 2021;9(6):373\u201392.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1908_CR7","doi-asserted-by":"publisher","DOI":"10.15420\/japsc.2023.68","volume":"3","author":"DTW Lui","year":"2024","unstructured":"Lui DTW, Ako J, Dalal J, et al. Obesity in the Asia-Pacific region: current perspectives. J Asian Pac Soc Cardiol. 2024;3:e21.","journal-title":"J Asian Pac Soc Cardiol"},{"issue":"11","key":"1908_CR8","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1111\/dom.15238","volume":"25","author":"K Chen","year":"2023","unstructured":"Chen K, Shen Z, Gu W, et al. Prevalence of obesity and associated complications in China: a cross-sectional, real-world study in 15.8 million adults. Diabetes Obes Metab. 2023;25(11):3390\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1908_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1908_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"Suppl 3","key":"1908_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1\u2013203.","journal-title":"Endocr Pract"},{"issue":"2","key":"1908_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1037\/amp0000517","volume":"75","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235\u201351.","journal-title":"Am Psychol"},{"issue":"1","key":"1908_CR13","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.123.001045","volume":"77","author":"M Kokkorakis","year":"2025","unstructured":"Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025;77(1):100002.","journal-title":"Pharmacol Rev"},{"key":"1908_CR14","unstructured":"American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S167\u2013S80."},{"issue":"6","key":"1908_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(21)00047-4","volume":"9","author":"Q Zeng","year":"2021","unstructured":"Zeng Q, Li N, Pan XF, Chen L, Pan A. Clinical management and treatment of obesity in China. Lancet Diabetes Endocrinol. 2021;9(6):393\u2013405.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1908_CR16","doi-asserted-by":"publisher","first-page":"e1339","DOI":"10.1210\/clinem\/dgab848","volume":"107","author":"WT Garvey","year":"2022","unstructured":"Garvey WT. New horizons. A new paradigm for treating to target with second-generation obesity medications. J Clin Endocrinol Metab. 2022;107(4):e1339\u201347.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1908_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12916-016-0735-y","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016;14(1):191.","journal-title":"BMC Med"},{"key":"1908_CR18","unstructured":"National Health Commission of the People\u2019s Republic of China. Guideline for diagnosis and treatment of obesity (2024 edition). 2024. https:\/\/www.gov.cn\/zhengce\/zhengceku\/202410\/content_6981734.htm. Accessed May 26 2025."},{"key":"1908_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101633","volume":"66","author":"T Zimmermann","year":"2022","unstructured":"Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633.","journal-title":"Mol Metab"},{"issue":"6","key":"1908_CR20","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","volume":"79","author":"PN Newsome","year":"2023","unstructured":"Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J Hepatol. 2023;79(6):1557\u201365.","journal-title":"J Hepatol"},{"key":"1908_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2019.110696","volume":"503","author":"MJ Pereira","year":"2020","unstructured":"Pereira MJ, Thombare K, Sarsenbayeva A, et al. Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes. Mol Cell Endocrinol. 2020;503:110696.","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"1908_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/14656566.2024.2356254","volume":"25","author":"P Gogineni","year":"2024","unstructured":"Gogineni P, Melson E, Papamargaritis D, Davies M. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Expert Opin Pharmacother. 2024;25(7):801\u201318.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"1908_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4103\/ijem.ijem_442_23","volume":"28","author":"WR Sidrak","year":"2024","unstructured":"Sidrak WR, Kalra S, Kalhan A. Approved and emerging hormone-based anti-obesity medications: a review article. Indian J Endocrinol Metab. 2024;28(5):445\u201360.","journal-title":"Indian J Endocrinol Metab"},{"issue":"3","key":"1908_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","volume":"34","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri N, Charlton M, Gray M, Noureddin M. The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists. Expert Opin Investig Drugs. 2025;34(3):169\u201395.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"1908_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","volume":"12","author":"CW le Roux","year":"2024","unstructured":"le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1908_CR26","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","volume":"67","author":"M Bl\u00fcher","year":"2024","unstructured":"Bl\u00fcher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470\u201382.","journal-title":"Diabetologia"},{"issue":"4","key":"1908_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"1908_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/oby.24184","volume":"33","author":"S Wharton","year":"2025","unstructured":"Wharton S, le Roux CW, Kosiborod MN, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE\u2122-1 and -2). Obesity (Silver Spring). 2025;33(1):67\u201377.","journal-title":"Obesity (Silver Spring)"},{"key":"1908_CR29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2600751","author":"CW le Roux","year":"2026","unstructured":"le Roux CW, Wharton S, Startseva E, et al. Survodutide once weekly for the treatment of adults with obesity. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/nejmoa2600751.","journal-title":"N Engl J Med"},{"key":"1908_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2025.171380","volume":"187","author":"CJ Bailey","year":"2025","unstructured":"Bailey CJ, Flatt PR, Conlon JM. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025;187:171380.","journal-title":"Peptides"},{"issue":"2","key":"1908_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/endrev\/bnaf036","volume":"47","author":"JW Son","year":"2025","unstructured":"Son JW, le Roux CW, Bl\u00fcher M, Nauck MA, Lim S. Novel GLP-1-based medications for type 2 diabetes and obesity. Endocr Rev. 2025;47(2):159\u201377.","journal-title":"Endocr Rev"},{"issue":"7","key":"1908_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jama.2024.9217","volume":"332","author":"L Zhao","year":"2024","unstructured":"Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024;332(7):551\u201360.","journal-title":"JAMA"},{"issue":"22","key":"1908_CR33","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","volume":"392","author":"L Ji","year":"2025","unstructured":"Ji L, Jiang H, Bi Y, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med. 2025;392(22):2215\u201325.","journal-title":"N Engl J Med"},{"issue":"1","key":"1908_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","volume":"7","author":"X Xu","year":"2022","unstructured":"Xu X, Poulsen KL, Wu L, et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH). Signal Transduct Target Ther. 2022;7(1):287.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1908_CR35","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","volume":"150","author":"MV Machado","year":"2016","unstructured":"Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016;150(8):1769\u201377.","journal-title":"Gastroenterology"},{"issue":"10464","key":"1908_CR36","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404(10464):1761\u201378.","journal-title":"Lancet"},{"key":"1908_CR37","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"issue":"8","key":"1908_CR38","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s00125-023-05947-y","volume":"66","author":"NJ Wewer Albrechtsen","year":"2023","unstructured":"Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, et al. 100 years of glucagon and 100 more. Diabetologia. 2023;66(8):1378\u201394.","journal-title":"Diabetologia"},{"issue":"5","key":"1908_CR39","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","volume":"81","author":"EJ Lawitz","year":"2024","unstructured":"Lawitz EJ, Fraessdorf M, Neff GW, et al. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J Hepatol. 2024;81(5):837\u201346.","journal-title":"J Hepatol"},{"issue":"7","key":"1908_CR40","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41573-025-01231-3","volume":"24","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24(7):570.","journal-title":"Nat Rev Drug Discov"},{"key":"1908_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100127","volume":"12","author":"W Ghusn","year":"2024","unstructured":"Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024;12:100127.","journal-title":"Obes Pillars"},{"key":"1908_CR42","doi-asserted-by":"crossref","unstructured":"Thomsen RW, Mailhac A, L\u00f8hde JB, Potteg\u00e5rd A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27 Suppl 2(Suppl 2):66\u201388.","DOI":"10.1111\/dom.16364"},{"issue":"4","key":"1908_CR43","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/dom.16167","volume":"27","author":"CW le Roux","year":"2025","unstructured":"le Roux CW, Steen O, Lucas KJ, et al. Subgroup analysis by sex and baseline BMI in people with a BMI \u226527 kg\/m(2) in the phase 2 trial of survodutide, a glucagon\/GLP-1 receptor dual agonist. Diabetes Obes Metab. 2025;27(4):1773\u201382.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1908_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","volume":"12","author":"JJ Gorgojo-Mart\u00ednez","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145.","journal-title":"J Clin Med"},{"issue":"1","key":"1908_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40265-025-02263-0","volume":"86","author":"SK Kunutsor","year":"2026","unstructured":"Kunutsor SK, Seidu S. Safety and tolerability of glucagon-like peptide-1 receptor agonists: a state-of-the-art narrative review. Drugs. 2026;86(1):11\u201336.","journal-title":"Drugs"},{"issue":"3-4","key":"1908_CR46","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3\u20134):202\u201330.","journal-title":"Rev Diabet Stud"},{"issue":"7","key":"1908_CR47","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/oby.24299","volume":"33","author":"DM Bushnell","year":"2025","unstructured":"Bushnell DM, Fung S, Brod M, et al. Development and validation of an eating behavior patient-reported outcome measure in people living with obesity or overweight. Obesity Silver Spring. 2025;33(7):1249\u201362.","journal-title":"Obesity Silver Spring"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01908-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01908-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01908-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:21:46Z","timestamp":1790655706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01908-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1908"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01908-x","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Boehringer Ingelheim was involved in the study design, data collection, data analysis and preparation of the manuscript. Yinan Zhu, Liying Jin, Isabel M. Kloer are employees of Boehringer Ingelheim. Linong Ji reports receiving consulting or lecture fees from Eli Lilly, Novo Nordisk, Merck, Bayer, Sanofi-Aventis, MSD, AstraZeneca, Boehinger Ingelheim, Abbott, Fosun Pharma, Innovent Biologics, Gan & Lee Pharmaceuticals, Sinocare, Sibionics. Liming Chen reports receiving research funding from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Gan & Lee, Hansoh, Hengrui, and Novo Nordisk. Zhifeng Cheng, Yibing Lu, Yan Yang, and Fangming Fu declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial protocol was approved by the respective Institutional Review Boards or Independent Ethics Committees of all participating centers (leading site: Ethics Review Committee of Peking University People\u2019s Hospital; approval number: 2023PHA128-001; full list in Table\n                      \n                      ), in accordance with national and international regulations, including the Declaration of Helsinki, the International Council for Harmonization Harmonized Guideline for Good Clinical Practice, and the trial sponsor\u2019s standard operating procedures. Written informed consent was signed by all participants before entering the trial. The trial protocol was reported following the guidelines of Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT). The SPIRIT 2025 checklist was provided in\n                      Table S6\n                      . In this trial, assessment scales including Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) and Columbia-Suicide Severity Rating Scale (C-SSRS) were used with appropriate permissions and in accordance with licensing requirements. The Eating Behavior patients-reported outcome (EB PRO) and Patient Health Questionnaire-9 (PHQ-9) were used in compliance with its open-access terms.","order":2,"name":"Ethics","label":"Ethical Statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}